Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi)

NCT02186886 is registered in ClinicalTrials.gov with Kliniken im Naturpark Altmuehltal as lead sponsor.

NCT NCT02186886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02186886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi)
Lead sponsor
Kliniken im Naturpark Altmuehltal
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2014
Completion date
December 31, 2015
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis